-
- Humam Kadara
- 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
-
- Paul Scheet
- 2The University of Texas Graduate School of Biomedical Sciences, Houston, Texas.
-
- Ignacio I. Wistuba
- 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
-
- Avrum E. Spira
- 4Section of Computational Biomedicine, Boston University School of Medicine, Boston University, Boston, Massachusetts.
説明
<jats:title>Abstract</jats:title> <jats:p>The majority of cancer-related deaths in the United States and worldwide are attributed to lung cancer. There are more than 90 million smokers in the United States who represent a significant population at elevated risk for lung malignancy. In other epithelial tumors, it has been shown that if neoplastic lesions can be detected and treated at their intraepithelial stage, patient prognosis is significantly improved. Thus, new strategies to detect and treat lung preinvasive lesions are urgently needed in order to decrease the overwhelming public health burden of lung cancer. Limiting these advances is a poor knowledge of the earliest events that underlie lung cancer development and that would constitute markers and targets for early detection and prevention. This review summarizes the state of knowledge of human lung cancer pathogenesis and the molecular pathology of premalignant lung lesions, with a focus on the molecular premalignant field that associates with lung cancer development. Lastly, we highlight new approaches and models to study genome-wide alterations in human lung premalignancy in order to facilitate the discovery of new markers for early detection and prevention of this fatal disease. Cancer Prev Res; 9(7); 518–27. ©2016 AACR.</jats:p>
収録刊行物
-
- Cancer Prevention Research
-
Cancer Prevention Research 9 (7), 518-527, 2016-06-30
American Association for Cancer Research (AACR)
